肿瘤学:Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
原文摘录:This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory).
关注理由:这条肿瘤学内容涉及相关临床或研究问题,建议查看原文中的方法与适用范围。